S1P RECEPTOR ANTAGONIST Russian patent published in 2011 - IPC C07C257/22 C07C317/36 C07D307/46 C07D333/22 A61P13/00 A61K31/33 A61P43/00 C07D295/18 A61P7/02 A61P11/00 A61K31/277 A61P35/00 A61P13/12 A61P9/00 A61K31/155 A61P27/02 A61K31/445 

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds - arylamidrazone derivatives of formula ,

where R¹ is a C₂-C₈ alkyl group or a C₂-C₈ alkoxy group, which can be substituted with a halogen or a C₁-C₈ alkoxy group; a 5-7-member aromatic heterocycle containing 1 or 2 oxygen, nitrogen or sulphur atoms, or phenyl, which can be substituted with a halogen, a C₁-C₈ alkyl group, a haloC₁-C₈alkyl group or a C₁-C₈alkoxy group; or NR⁴R⁵; R² and R³ are identical or different, and each is a hydrogen atom, a halogen atom, a halogenC₁-C₈alkyl group, a C₁-C₈alkyl group, a C₂-C₆alkynyl group, a C₁-C₈alkoxy group, a cyano group, a C₂-C₆alkanoyl group or a C₁-C₈alkylsulphonyl group; A is a benzene, pyridine, quinoline or isoquinoline ring; D is a single bond or methylene; m assumes values from 1 to 3 and n assumes values from 1 to 5, having antagonistic effect on S1P₃ receptors, as well as to medicinal agents and pharmaceutical compositions containing such compounds as an active ingredient.

EFFECT: improved properties.

13 cl, 161 ex, 19 tbl